CoChat

The Role of Hypoxia and Exploitation of the Hypoxic Environment in Hematologic Malignancies

Muz, Barbara, de la Puente, Pilar, Azab, Feda, Luderer, Micah, Azab, Abdel Kareem · 2014 · Molecular Cancer Research
Cited by 52

The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.

Abstract

Tumor hypoxia is a well-described phenomenon during the progression of solid tumors affecting cell signaling pathways and cell metabolism; however, its role in hematologic malignancies has not been given the same attention in the literature. Therefore, this review focuses on the comparative differences between solid and hematologic malignancies with emphasis on the role of hypoxia during tumorigenesis and progression. In addition, contribution of the bone marrow and angiogenic environment are also discussed. Insight is provided into the role of hypoxia in metastatic spread, stemness, and drug resistance in hematologic conditions. Finally, emerging therapeutic strategies such as small-molecule prodrugs and hypoxia-inducible factor (HIF) targeting approaches are outlined to combat hypoxic cells and/or adaptive mechanisms in the treatment of hematologic malignancies. Mol Cancer Res; 12(10); 1347–54. ©2014 AACR.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/1541-7786.mcr-14-0028

Cites

14 of 14 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 14 references

Research works printed but not linked: 69

  1. Krock, 2011, Hypoxia-induced angiogenesis: good and evil, Genes Cancer, 2, 1117, 10.1177/1947601911423654 · DOI · Paper page
  2. Sanchez, 2012, p38 MAPK: a mediator of hypoxia-induced cerebrovascular inflammation, J Alzheimers Dis, 32, 587, 10.3233/JAD-2012-120829 · DOI
  3. Tafani, 2011, Hypoxia-increased RAGE and P2 × 7R expression regulates tumor cell invasion through phosphorylation of Erk1/2 and Akt and nuclear translocation of NF-{kappa}B, Carcinogenesis, 32, 1167, 10.1093/carcin/bgr101 · DOI · Paper page
  4. Grant, 1963, Bone marrow gas tensions, bone marrow blood flow, and erythropoiesis in man, Ann Intern Med, 58, 801, 10.7326/0003-4819-58-5-801 · DOI · Paper page
  5. Colla, 2010, Low bone marrow oxygen tension and hypoxia-inducible factor-1alpha overexpression characterize patients with multiple myeloma: role on the transcriptional and proangiogenic profiles of CD138(+) cells, Leukemia, 24, 1967, 10.1038/leu.2010.193 · DOI
  6. Sipkins, 2005, In vivo imaging of specialized bone marrow endothelial microdomains for tumour engraftment, Nature, 435, 969, 10.1038/nature03703 · DOI · Paper page
  7. Levesque, 2007, Hematopoietic progenitor cell mobilization results in hypoxia with increased hypoxia-inducible transcription factor-1 alpha and vascular endothelial growth factor A in bone marrow, Stem Cells, 25, 1954, 10.1634/stemcells.2006-0688 · DOI · Paper page
  8. Parmar, 2007, Distribution of hematopoietic stem cells in the bone marrow according to regional hypoxia, Proc Natl Acad Sci U S A, 104, 5431, 10.1073/pnas.0701152104 · DOI · Paper page
  9. Folkman, 1971, Tumor angiogenesis: therapeutic implications, N Engl J Med, 285, 1182, 10.1056/NEJM197111182852108 · DOI · Paper page
  10. Azab, 2012, Hypoxia promotes dissemination of multiple myeloma through acquisition of epithelial to mesenchymal transition-like features, Blood, 119, 5782, 10.1182/blood-2011-09-380410 · DOI · Paper page
  11. Tannock, 1978, Cell kinetics and chemotherapy: a critical review, Cancer Treat Rep, 62, 1117
  12. Giatromanolaki, 2010, Hypoxia and activated VEGF/receptor pathway in multiple myeloma, Anticancer Res, 30, 2831
  13. Hu, 2009, Inhibition of hypoxia-inducible factor-1 function enhances the sensitivity of multiple myeloma cells to melphalan, Mol Cancer Ther, 8, 2329, 10.1158/1535-7163.MCT-09-0150 · DOI
  14. Martin, 2010, Hypoxia-inducible factor-2 is a novel regulator of aberrant CXCL12 expression in multiple myeloma plasma cells, Haematologica, 95, 776, 10.3324/haematol.2009.015628 · DOI
  15. Storti, 2013, Hypoxia-inducible factor (HIF)-1alpha suppression in myeloma cells blocks tumoral growth in vivo inhibiting angiogenesis and bone destruction, Leukemia, 27, 1697, 10.1038/leu.2013.24 · DOI
  16. Hu, 2010, Targeting the multiple myeloma hypoxic niche with TH-302, a hypoxia-activated prodrug, Blood, 116, 1524, 10.1182/blood-2010-02-269126 · DOI · Paper page
  17. Passam, 2009, Histological expression of angiogenic factors: VEGF, PDGFRalpha, and HIF-1alpha in Hodgkin lymphoma, Pathol Res Pract, 205, 11, 10.1016/j.prp.2008.07.007 · DOI
  18. Evens, 2008, Hypoxia inducible factor-alpha activation in lymphoma and relationship to the thioredoxin family, Br J Haematol, 141, 676, 10.1111/j.1365-2141.2008.07093.x · DOI
  19. Argyriou, 2011, Hypoxia-inducible factors in mantle cell lymphoma: implication for an activated mTORC1–>HIF-1alpha pathway, Ann Hematol, 90, 315, 10.1007/s00277-010-1070-6 · DOI
  20. Deeb, 2011, Hypoxia-inducible factor-1alpha protein expression is associated with poor survival in normal karyotype adult acute myeloid leukemia, Leuk Res, 35, 579, 10.1016/j.leukres.2010.10.020 · DOI
  21. Wellmann, 2004, Activation of the HIF pathway in childhood ALL, prognostic implications of VEGF, Leukemia, 18, 926, 10.1038/sj.leu.2403332 · DOI
  22. Benito, 2011, Pronounced hypoxia in models of murine and human leukemia: high efficacy of hypoxia-activated prodrug PR-104, PLoS ONE, 6, e23108, 10.1371/journal.pone.0023108 · DOI
  23. Ghosh, 2009, Aberrant regulation of pVHL levels by microRNA promotes the HIF/VEGF axis in CLL B cells, Blood, 113, 5568, 10.1182/blood-2008-10-185686 · DOI · Paper page
  24. Jensen, 2000, Increased cellular hypoxia and reduced proliferation of both normal and leukaemic cells during progression of acute myeloid leukaemia in rats, Cell Prolif, 33, 381, 10.1046/j.1365-2184.2000.00183.x · DOI
  25. Frolova, 2012, Regulation of HIF-1alpha signaling and chemoresistance in acute lymphocytic leukemia under hypoxic conditions of the bone marrow microenvironment, Cancer Biol Ther, 13, 858, 10.4161/cbt.20838 · DOI
  26. Azab, 2013, The influence of hypoxia on CML trafficking through modulation of CXCR4 and E-cadherin expression, Leukemia, 27, 961, 10.1038/leu.2012.353 · DOI
  27. de la Puente, 2013, Cell trafficking of endothelial progenitor cells in tumor progression, Clin Cancer Res, 19, 3360, 10.1158/1078-0432.CCR-13-0462 · DOI · Paper page
  28. Rajkumar, 2002, Bone marrow angiogenesis in 400 patients with monoclonal gammopathy of undetermined significance, multiple myeloma, and primary amyloidosis, Clin Cancer Res, 8, 2210
  29. Minoia, 2013, Changes in angiogenesis and hypoxia-inducible factor-1alpha protein expression in relapsed/refractory indolent non-Hodgkin lymphomas, Br J Haematol, 163, 640, 10.1111/bjh.12560 · doi:10.1111/bjh.12560
  30. Dejean, 2011, Hypoxia-microRNA-16 downregulation induces VEGF expression in anaplastic lymphoma kinase (ALK)-positive anaplastic large-cell lymphomas, Leukemia, 25, 1882, 10.1038/leu.2011.168 · DOI
  31. Tadokoro, 2013, Exosomes derived from hypoxic leukemia cells enhance tube formation in endothelial cells, J Biol Chem, 288, 34343, 10.1074/jbc.M113.480822 · DOI · Paper page
  32. Dong-Feng, 2012, Silencing HIF-1alpha reduces the adhesion and secretion functions of acute leukemia hBMSCs, Braz J Med Biol Res, 45, 906
  33. Yang, 2008, TWIST activation by hypoxia inducible factor-1 (HIF-1): implications in metastasis and development, Cell Cycle, 7, 2090, 10.4161/cc.7.14.6324 · DOI · Paper page
  34. Mak, 2010, ERbeta impedes prostate cancer EMT by destabilizing HIF-1alpha and inhibiting VEGF-mediated snail nuclear localization: implications for Gleason grading, Cancer Cell, 17, 319, 10.1016/j.ccr.2010.02.030 · DOI · Paper page
  35. Azab, 2009, RhoA and Rac1 GTPases play major and differential roles in stromal cell-derived factor-1-induced cell adhesion and chemotaxis in multiple myeloma, Blood, 114, 619, 10.1182/blood-2009-01-199281 · DOI · Paper page
  36. Azab, 2012, P-selectin glycoprotein ligand regulates the interaction of multiple myeloma cells with the bone marrow microenvironment, Blood, 119, 1468, 10.1182/blood-2011-07-368050 · DOI · Paper page
  37. Azab, 2009, CXCR4 inhibitor AMD3100 disrupts the interaction of multiple myeloma cells with the bone marrow microenvironment and enhances their sensitivity to therapy, Blood, 113, 4341, 10.1182/blood-2008-10-186668 · DOI · Paper page
  38. Ghobrial, 2012, Myeloma as a model for the process of metastasis: implications for therapy, Blood, 120, 20, 10.1182/blood-2012-01-379024 · DOI · Paper page
  39. Schelter, 2011, Tissue inhibitor of metalloproteinases-1-induced scattered liver metastasis is mediated by hypoxia-inducible factor-1alpha, Clin Exp Metastasis, 28, 91, 10.1007/s10585-010-9360-x · DOI
  40. Fiegl, 2009, CXCR4 expression and biologic activity in acute myeloid leukemia are dependent on oxygen partial pressure, Blood, 113, 1504, 10.1182/blood-2008-06-161539 · DOI · Paper page
  41. Vaupel, 2001, Oxygen status of malignant tumors: pathogenesis of hypoxia and significance for tumor therapy, Semin Oncol, 28, 29, 10.1016/S0093-7754(01)90210-6 · DOI · Paper page
  42. Das, 2008, Hypoxia enhances tumor stemness by increasing the invasive and tumorigenic side population fraction, Stem Cells, 26, 1818, 10.1634/stemcells.2007-0724 · DOI · Paper page
  43. Cipolleschi, 1993, The role of hypoxia in the maintenance of hematopoietic stem cells, Blood, 82, 2031, 10.1182/blood.V82.7.2031.2031 · DOI · Paper page
  44. Rohwer, 2011, Hypoxia-mediated drug resistance: novel insights on the functional interaction of HIFs and cell death pathways, Drug Resist Updat, 14, 191, 10.1016/j.drup.2011.03.001 · DOI · Paper page
  45. Axelson, 2005, Hypoxia-induced dedifferentiation of tumor cells—a mechanism behind heterogeneity and aggressiveness of solid tumors, Semin Cell Dev Biol, 16, 554, 10.1016/j.semcdb.2005.03.007 · DOI · Paper page
  46. Diabira, 2008, Gliomagenesis and neural stem cells: key role of hypoxia and concept of tumor “neo-niche”, Med Hypotheses, 70, 96, 10.1016/j.mehy.2007.04.024 · DOI
  47. Blazek, 2007, Daoy medulloblastoma cells that express CD133 are radioresistant relative to CD133− cells, and the CD133+ sector is enlarged by hypoxia, Int J Radiat Oncol Biol Phys, 67, 1, 10.1016/j.ijrobp.2006.09.037 · DOI · Paper page
  48. Tung, 2007, Targeting hedgehog in cancer stem cells: how a paradigm shift can improve treatment response, Future Oncol, 3, 569, 10.2217/14796694.3.5.569 · DOI
  49. Katoh, 2008, WNT signaling in stem cell biology and regenerative medicine, Curr Drug Targets, 9, 565, 10.2174/138945008784911750 · DOI
  50. Kawano, 2013, Hypoxia reduces CD138 expression and induces an immature and stem cell–like transcriptional program in myeloma cells, Int J Oncol, 43, 1809, 10.3892/ijo.2013.2134 · DOI
  51. Hernandez-Luna, 2013, Hypoxia inducible factor-1alpha induces chemoresistance phenotype in non-Hodgkin lymphoma cell line via up-regulation of Bcl-(xL), Leuk Lymphoma, 54, 1048, 10.3109/10428194.2012.733874 · DOI
  52. Zhang, 2012, HIF1alpha is required for survival maintenance of chronic myeloid leukemia stem cells, Blood, 119, 2595, 10.1182/blood-2011-10-387381 · DOI · Paper page
  53. Rouault-Pierre, 2013, HIF-2alpha protects human hematopoietic stem/progenitors and acute myeloid leukemic cells from apoptosis induced by endoplasmic reticulum stress, Cell Stem Cell, 13, 549, 10.1016/j.stem.2013.08.011 · DOI · Paper page
  54. He, 2013, HIF-1alpha downregulates miR-17/20a directly targeting p21 and STAT3: a role in myeloid leukemic cell differentiation, Cell Death Differ, 20, 408, 10.1038/cdd.2012.130 · DOI
  55. Matsunaga, 2012, Elevated HIF-1alpha expression of acute myelogenous leukemia stem cells in the endosteal hypoxic zone may be a cause of minimal residual disease in bone marrow after chemotherapy, Leuk Res, 36, e122, 10.1016/j.leukres.2012.02.028 · DOI
  56. Raje, 2011, Advances in the biology and treatment of bone disease in multiple myeloma, Clin Cancer Res, 17, 1278, 10.1158/1078-0432.CCR-10-1804 · DOI · Paper page
  57. Duan, 2008, Potent and highly selective hypoxia-activated achiral phosphoramidate mustards as anticancer drugs, J Med Chem, 51, 2412, 10.1021/jm701028q · DOI · Paper page
  58. Brown, 1984, Clinical trials of radiosensitizers: what should we expect?, Int J Radiat Oncol Biol Phys, 10, 425, 10.1016/0360-3016(84)90063-4 · DOI
  59. Patterson, 2002, Bioreductively activated antitumor N-oxides: the case of AQ4N, a unique approach to hypoxia-activated cancer chemotherapy, Drug Metab Rev, 34, 581, 10.1081/DMR-120005659 · DOI · Paper page
  60. Albertella, 2008, Hypoxia-selective targeting by the bioreductive prodrug AQ4N in patients with solid tumors: results of a phase I study, Clin Cancer Res, 14, 1096, 10.1158/1078-0432.CCR-07-4020 · DOI · Paper page
  61. Tredan, 2009, The hypoxia-activated ProDrug AQ4N penetrates deeply in tumor tissues and complements the limited distribution of mitoxantrone, Cancer Res, 69, 940, 10.1158/0008-5472.CAN-08-0676 · DOI
  62. von Pawel, 2000, Tirapazamine plus cisplatin versus cisplatin in advanced non-small-cell lung cancer: a report of the international CATAPULT I study group. Cisplatin and tirapazamine in subjects with advanced previously untreated non-small-cell lung tumors, J Clin Oncol, 18, 1351, 10.1200/JCO.2000.18.6.1351 · DOI · Paper page
  63. Hu, 2013, Synergistic induction of apoptosis in multiple myeloma cells by bortezomib and hypoxia-activated prodrug TH-302, in vivo and in vitro, Mol Cancer Ther, 12, 1763, 10.1158/1535-7163.MCT-13-0123 · DOI
  64. Meng, 2012, Molecular and cellular pharmacology of the hypoxia-activated prodrug TH-302, Mol Cancer Ther, 11, 740, 10.1158/1535-7163.MCT-11-0634 · DOI · Paper page
  65. Patterson, 2007, Mechanism of action and preclinical antitumor activity of the novel hypoxia-activated DNA cross-linking agent PR-104, Clin Cancer Res, 13, 3922, 10.1158/1078-0432.CCR-07-0478 · DOI · Paper page
  66. McKeage, 2011, A phase I trial of PR-104, a pre-prodrug of the bioreductive prodrug PR-104A, given weekly to solid tumour patients, BMC Cancer, 11, 432, 10.1186/1471-2407-11-432 · DOI · Paper page
  67. Portwood, 2013, Activity of the hypoxia-activated prodrug, TH-302, in preclinical human acute myeloid leukemia (AML) models, Clin Cancer Res, 19, 6506, 10.1158/1078-0432.CCR-13-0674 · DOI
  68. Yi, 2013, Final report of phase I/II study of PR104, a hypoxia-activated pro-drug, in relapsed/refractory acute leukemia 2013, J Clin Oncol, 31
  69. Lee, 2012, From stem cells to cancer stem cells: HIF takes the stage, Curr Opin Cell Biol, 24, 232, 10.1016/j.ceb.2012.01.005 · DOI

Cited by

See all 52

Metadata

Authors
Muz, B., de la Puente, P., Azab, F., Luderer, M., & Azab, A. K.
Affiliations
Department of Radiation Oncology, Cancer Biology Division, Washington University in Saint Louis School of Medicine, St. Louis, Missouri.
Venue
Molecular Cancer Research
Published
2014-10-01
Volume
12
Issue
10
Pages
1347-1354
ISSN
  • 1541-7786
  • 1557-3125
Cited by
52
References
14
Language
en

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The Role of Hypoxia and Exploitation of the Hypoxic Environment in Hematologic Malignancies. https://app.cochat.ai/papers/10.1158/1541-7786.mcr-14-0028
The paper
Muz, B., de la Puente, P., Azab, F., Luderer, M., & Azab, A. K. (2014). The Role of Hypoxia and Exploitation of the Hypoxic Environment in Hematologic Malignancies. Molecular Cancer Research. https://doi.org/10.1158/1541-7786.mcr-14-0028

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.